ANGONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends May 31
ANGIODYNAMICS INC
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 8, 2026
$11.39+0.15 (+1.33%)
Close on Oct 19, 2026
- Market cap
- $478.63M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2026
Gross margin
54.6%+0.7 pts over 5 years
Operating margin
-12.5%−0.3 pts over 5 years
Net margin
-11.5%−0.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +9.5% | -1.9% | +1.9% | -1.0% | |
| Gross profit | +10.9% | +0.1% | +2.2% | +0.0% | |
| Free cash flow | – | – | -51.5% | -35.8% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | 1.0% | -7.1% | -20.8% | |
| Return on assets | 0.7% | -5.5% | -13.4% | |
| Current ratio | 2.15 | 2.45 | 2.19 | |
| Debt to equity | 0.19 | – | – | |
| Net debt to EBITDA | 3.58× | – | – | |
| Interest coverage | -3.9× | -41.0× | – | |
| Inventory turnover | 2.3× | 2.5× | 2.5× | |
| Capex to revenue | 1.1% | 1.8% | 0.8% | |
| Diluted shares | 37M | 38M | 42M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Angiodynamics generated $48.65M from operations and spent $19.34M on capital expenditure, dividends and share buybacks. 91% of that went back into the business.
Generated
$48.65M
Used
$19.34M
Capital expenditure$17.67M91%Dividends$00%Share buybacks$1.67M9%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-11.5%
×Asset turnover1.17×
×Equity multiplier1.55×
=Return on equity, FY2026-20.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | -11.5% | 1.17× | 1.55× | -20.8% |
| FY2025 | -11.6% | 0.98× | 1.54× | -17.5% |
| FY2024 | -60.7% | 0.71× | 1.46× | -63.1% |
| FY2023 | -15.5% | 0.62× | 1.35× | -13.1% |
| FY2022 | -8.4% | 0.57× | 1.29× | -6.1% |
| FY2021 | -10.8% | 0.50× | 1.29× | -7.1% |
| FY2020 | -63.1% | 0.37× | 1.34× | -31.2% |
| FY2019 | 22.7% | 0.35× | 1.33× | 10.6% |
| FY2018 | 6.2% | 0.37× | 1.34× | 3.1% |
| FY2017 | 1.9% | 0.38× | 1.40× | 1.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
4of 8 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero-$36.74M
- Cash generatingOperating cash flow above zero$3.09M
- Return on assets improvedROA up on the prior year-10.7% → -13.1%
- Earnings backed by cashOperating cash flow above net income$3.09M vs -$36.74M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.21 → 2.19
- No dilutionShare count did not rise41M → 42M
- Gross margin improvedGross margin up on the prior year53.92% → 54.62%
- More efficientAsset turnover rose0.92 → 1.14